Rifaximin EIR ( DrugBank: Rifaximin )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	2

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02240108 (ClinicalTrials.gov)	October 28, 2014	11/9/2014	One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease	A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease	Crohn's Disease	Drug: Rifaximin EIR;Drug: Placebo	Bausch Health Americas, Inc.	Salix Pharmaceuticals, Inc. a division of Bausch Health US, LLC	Terminated	18 Years	N/A	All	81	Phase 3	United States
2	NCT02240121 (ClinicalTrials.gov)	August 21, 2014	11/9/2014	One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease	A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease	Crohn's Disease	Drug: Rifaximin EIR;Drug: Placebo	Bausch Health Americas, Inc.	Salix Pharmaceuticals, Inc. a division of Bausch Health US, LLC	Terminated	18 Years	N/A	All	80	Phase 3	United States